Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (NASDAQ: APYX) is a cutting-edge energy technology company that develops, manufactures, and markets advanced medical devices for the cosmetic and surgical markets globally. The company operates through two primary segments: Advanced Energy and Original Equipment Manufacturing (OEM).
Under the Renuvion brand, Apyx Medical offers proprietary helium plasma and radiofrequency technology, which is widely used in cosmetic surgery. This innovative technology provides surgeons with the ability to apply controlled heat to tissues, optimizing results in procedures such as body contouring and liposuction. The J-Plasma system, marketed for surgical applications within hospitals, minimizes unintended tissue trauma during surgical operations.
Recent achievements underline Apyx Medical's commitment to advancing medical technology. In the third quarter of 2023, the company reported a 31% year-over-year increase in total revenue, highlighted by a 39% increase in Advanced Energy sales. Significant strides were made in developing the Apyx One Generator and associated accessories, which have seen robust global demand.
From a financial perspective, Apyx Medical continues to strengthen its position. For the year ending December 31, 2023, the company secured a new five-year credit agreement with Perceptive Advisors, providing up to $45 million in capital. This new agreement enhances the company's financial flexibility and supports its growth strategy.
The company's OEM segment collaborates with other medical device manufacturers to design, develop, and produce electrosurgical generators and related accessories. This segment saw a 14% year-over-year growth in revenue during the first three quarters of 2023.
Apyx Medical remains focused on leveraging regulatory clearances and expanding its market reach. Noteworthy is its active participation in industry conferences, such as the American Academy of Cosmetic Surgery’s Annual Meeting, where it showcases its innovative products and clinical findings. The company continues to invest in research and development to enhance its product offerings, and is committed to maintaining rigorous safety and efficacy standards, supported by an extensive portfolio of clinical evidence.
In summary, Apyx Medical Corporation is at the forefront of medical energy technology, providing innovative solutions that elevate patient care in both cosmetic and surgical markets. With a robust financial outlook, strategic industry partnerships, and a continuous drive for product excellence, Apyx Medical is poised for sustained growth and market leadership.
Apyx Medical (NASDAQ: APYX), developer of the proprietary Renuvion helium plasma and radiofrequency technology, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results release for March 13, 2025, before market opening.
The company will host a conference call at 8:30 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Interested parties can join via phone (877-407-9039 for domestic, 201-689-8470 for international) using access code 13751519, or through the company's webcast link and Investor Relations website section.
Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology, marketed as Renuvion in cosmetic surgery and J-Plasma in hospital surgical markets. The company's products are supported by over 90 clinical documents and provide controlled heat tissue treatment.
Apyx Medical (NASDAQ:APYX) has released preliminary revenue results for Q4 and full year 2024. The company expects Q4 total revenue between $14.1-14.3 million, down 3-4% year-over-year, with Advanced Energy revenue of $12.0-12.2 million (flat YoY) and OEM revenue of $2.1 million (down 17% YoY).
For full year 2024, total revenue is projected at $48.0-48.2 million, an 8% decrease YoY. Advanced Energy segment expects $38.5-38.7 million (down 11% YoY), while OEM revenue shows growth at $9.5 million (up 6% YoY).
Notable improvements include 25% quarter-over-quarter growth in Advanced Energy sales during Q4, doubled generator unit sales in H2 2024 compared to H1, and strong U.S. single-use handpiece sales. The company plans to launch its new AYON™ Body Contouring System in H2 2025, pending FDA clearance, targeting the growing market for loose skin treatments, particularly driven by GLP-1 drug-related weight loss.
Apyx Medical (NASDAQ:APYX) has submitted a 510(k) premarket notification to the FDA for its AYON Body Contouring System, nearly 90 days ahead of schedule. The system is designed as an all-in-one platform for surgical body contouring procedures.
The initial submission includes multiple functionalities: infiltration, dual aspiration for simultaneous users, ultrasound-assisted liposuction, electrocoagulation for excess tissue removal, volume enhancement capabilities, and Renuvion treatment for loose and lax skin. The company plans to expand AYON's indications with an additional 510(k) submission later this year to include power-assisted liposuction.
Apyx Medical (NASDAQ:APYX) announced its participation in the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, in New York. President and CEO Charlie Goodwin and CFO Matt Hill will conduct a fireside chat at 4:00pm ET and meet with investors throughout the day. The chat will be available via live webcast and replay on the company's investor relations website.
Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology marketed as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgical markets. These products provide controlled heat delivery to tissue, supported by over 90 clinical documents.
Apyx Medical (NASDAQ:APYX) announced that President and CEO Charles Goodwin and CFO Matt Hill will attend the 15th Annual Craig-Hallum Alpha Select Conference. The event will take place on November 19, 2024, at the Sheraton NY Times Square Hotel in New York, NY, featuring 1x1 meetings format.
Apyx Medical is an advanced energy technology company specializing in Helium Plasma Platform Technology products, marketed as Renuvion in cosmetic surgery and J-Plasma in hospital surgical markets. Their technology provides surgeons with controlled heat tissue treatment capabilities, supported by over 90 clinical documents.
Apyx Medical (NASDAQ:APYX) has secured a $7 million registered direct offering through a definitive purchase agreement with Nantahala Capital. The offering includes 3,000,000 shares of common stock at $1.18 per share and pre-funded warrants for up to 2,934,690 shares at $1.179 per warrant. The purchase price was calculated using the average closing price over five trading days prior to November 7, 2024. The company plans to use the proceeds for working capital and general corporate purposes. The offering closed on November 8, 2024, with no placement agent involved.
Apyx Medical reported Q3 2024 financial results with total revenue of $11.5 million, down 4% year-over-year. The company's Advanced Energy segment decreased 6% to $9.3 million, while OEM revenue increased 3% to $2.2 million. Despite overall decline, single-use handpiece revenue grew 9% overall and 15% in the U.S. The company secured $7.0 million through a registered direct offering and implemented cost-saving measures, including a 25% reduction in U.S. workforce expected to save $4.3 million annually. Updated 2024 guidance projects total revenue of $46.6-47.6 million, representing a 9-11% decrease from 2023, with net loss expected at approximately $25.0 million.
Apyx Medical (NASDAQ:APYX) announced it will release its third quarter fiscal year 2024 financial results before market opening on November 8th, 2024. The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. The call will be accessible via phone (877-407-9039 for domestic, 201-689-8470 for international callers) with access code 13749764, and through a live webcast on the company's Investor Relations website.
Apyx Medical (NASDAQ: APYX) announced that Renuvion has been named the #1 trusted body contouring technology by doctors in an independent survey. This recognition highlights Renuvion's effectiveness in targeting loose skin for body contouring procedures. Key points include:
- Renuvion is the first and only technology targeting loose skin from the inside out
- 4 out of 5 surgeons prefer Renuvion over other treatments following liposuction
- Over 350,000 patients have been treated with Renuvion
- Apyx Medical has secured four FDA 510(k) clearances in the past two years
- Renuvion is the only FDA-cleared device for contracting subcutaneous tissue and for use after liposuction
This recognition underscores Apyx Medical's commitment to providing evidence-based outcomes through advanced technology in plastic surgery.
Apyx Medical (NASDAQ:APYX) announced the publication of a peer-reviewed study in Plastic and Reconstructive Surgery—Global Open comparing their Renuvion Helium Plasma Technology to InMode's Bipolar RF System following liposuction or body contouring procedures. The study, involving over 450 patients, found that Renuvion exhibited statistically significant fewer adverse events (p-value <0.0001) compared to Bipolar RF.
Key findings include:
- 45 adverse events in 34 Renuvion patients vs. 93 in 62 Bipolar RF patients
- 28 procedure-related events with Renuvion vs. 69 with Bipolar RF
- Significantly fewer burns, hematomas, hypertrophic scars, and seromas with Renuvion
Researchers concluded that Renuvion may offer a safer alternative with shorter procedural times and higher patient satisfaction rates.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
What does Apyx Medical Corporation specialize in?
What are the key product lines of Apyx Medical?
What recent financial achievements has Apyx Medical reported?
What significant recent projects has Apyx Medical undertaken?
Who are the typical customers for Apyx Medical's Renuvion technology?
What recent strategic financial move has Apyx Medical made?
How does Apyx Medical contribute to the OEM market?
What role does research and development play at Apyx Medical?
Where can I find more information about Apyx Medical's products?
What industry events does Apyx Medical participate in?
